Cancers in 2010 attributable to ionising radiation exposure in the UK

DM Parkin*1 and SC Darby2
1Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK; 2Clinical Trial Service Unit & Epidemiological Studies Unit, University of Oxford, Oxford, UK

METHODS AND RESULTS

Radon

The chemically inert gas radon-222 arises from the uranium-238 present throughout the earth’s crust and is a ubiquitous air pollutant. If inhaled, radon itself is mostly exhaled immediately, but its short-lived progeny are solid and tend to deposit on the bronchial epithelium, where they may expose sensitive cells to alpha irradiation. Radon has been classified as carcinogenic to humans (IARC, 2001). Outdoor radon concentrations in the UK are low, but indoor concentrations are higher, especially in houses and other small buildings, and indoor radon at home is the largest source of exposure to natural ionising radiation. Gray et al (2009) used information on the distribution of measured radon gas concentrations in UK homes from a nationwide representative survey (Wrixon et al, 1988) together with estimates of the percentage increase in the risk of lung cancer per 100 Bq m−3 increase in the long-term average radon concentration at home, in people with well-documented smoking histories (Darby et al, 2005, 2006) to estimate the burden of fatal radon-induced lung cancer in the UK in 2006.

Table 2a shows the results from Gray et al (2009). Table 2b shows the estimated number of cases of lung cancer caused by radon in 2010, based on the number of deaths in Table 2a and the total number of deaths from lung cancer in the UK in 2006 (by age group and sex). It assumes that the fraction of lung cancer cases due to radon is the same as the fraction of lung cancer deaths (that is, that the risk of death from lung cancer in lung cancer patients is the same in radon-induced cases and other cases).

The 1376 cases of lung cancer attributable to residential radon represent 3.4% of the total number of lung cancer cases estimated to have occurred in the UK in 2010 (or 0.4% of all new cancers in 2010). Of these, 57% of the radon-induced cancers occurred in individuals aged 55–74 years. Most of the remainder occurred in individuals aged over 75, with 3% at ages <55 (Table 2b). Of the radon-induced lung cancers, 55% were in men. The vast majority of radon-induced lung cancers are caused jointly by radon and active smoking in the sense that the lung cancer could have been avoided by avoiding either exposure; radon alone was estimated to be responsible for only 157 deaths in 2006 (0.5% of lung cancer deaths) (Gray et al, 2009). This is equivalent to 182 cases in 2010 (0.45% of lung cancer cases, 0.06% of all cancers).

Medical exposures

Medical exposures to ionising radiation include those for diagnostic (X-rays and nuclear medicine) and therapeutic purposes (radiotherapy). Although we are concerned here with
evaluating the negative consequences – in terms of the number of cancer cases likely to be induced by such radiation – these should be set in the context of the substantial benefits accruing through the management of individual patients.

**Diagnostic X-rays** Diagnostic X-rays are the largest man-made source of radiation exposure to the general population, contributing about 15% of the total annual dose in the UK from all sources (see Table 1). Although diagnostic X-rays provide great benefits, their use involves a small risk of developing cancer. Berrington de Gonzalez and Darby (2004) estimated the extent of this risk on the basis of the annual number of diagnostic X-rays undertaken in the UK. They combined data on the frequency of diagnostic X-ray use in 1991–1996, the estimated radiation doses from X-rays to individual body organs, and risk models (based mainly on the Japanese atomic bomb survivors, see UNSCEAR, 2000), with population-based cancer incidence rates from the UK in 1989–92. They estimated the attributable fraction of cases for nine types of cancer, and for all radiation-inducible cancers (i.e., all cancers except lymphomas, multiple myeloma, and chronic lymphocytic leukaemia (CLL)). In their analysis, the cumulative risks (and attributable fractions) were calculated up to age 75. But, under the assumption that radiation-induced cancer risks persist indefinitely, the same population-attributable fractions (PAFs) should be applicable to cases occurring after age 75.

**Nuclear medicine** Small amounts of radiation are received through administration of radio-isotopes for diagnostic or therapeutic purposes. Three surveys of the frequency of different nuclear medicine procedures in the UK and the annual collective dose arising from them have been carried out by the HPA. Based on the most recent survey, which was carried out in 2003–4, the estimated total annual collective dose from diagnostic nuclear medicine procedures was 1620 man Sv, which was approximately 32% higher than at the time of the second survey in 1989, and 67% higher than at the time of the first survey in 1982 (Hart and Wall, 2005). The 2003–4 survey was the first to consider doses from therapeutic nuclear medicine procedures, and the estimated annual collective dose to the UK population from treatment of the three commonest disorders (thyroid carcinoma, thyrotoxicosis and non-toxic goitre) was 742 man Sv. The procedures with the largest contributions to estimated collective dose (> 50 man Sv) in 2003–4 are shown in Table 4.

The doses to different organs of the body can be estimated on the basis of the total administered activity for different procedures and conversion factors using estimates of the dose to different organs per unit activity administered. The estimates were taken from publications of the International Commission on Radiological Protection (ICRP, 1988, 1998). Thus, for example, the effective dose of $^{99m}$Tc phosphates is $5.7 \times 10^{-2} \text{ mSv MBq}^{-1}$, while the dose to the bladder is $4.8 \times 10^{-2} \text{ mSv MBq}^{-1}$ (in adults). We may therefore estimate the annual collective bladder dose in UK in 2003–4 as $601 \times (0.048/0.0057)$ or 5061 man Sv.

Organ-specific dose estimates were prepared for 2003–4, 1989 and 1982, with linear interpolation for the intervening years. For years prior to 1982, we assumed the same organ-specific dose profile as in 1982, with a linear diminution in exposure back to zero in 1950, the period around which diagnostic radio isotopes were coming into medical use in UK. For the years 2005–10, we assumed the same organ–specific dose profile as in 2003–4, with the same linear change in exposure as observed in the period 1989–2003/4.

Figure 1 shows the estimated annual collective dose for five specific organs and also the corresponding effective dose to the whole body. These collective doses for the whole population have been converted to average doses for individuals in each age and sex group in the population by multiplying the collective doses by weights proportional to the distribution of exposure in the different age and sex groups, and then dividing by the number of people in the appropriate population at risk. The age and sex distribution of exposures to radioactive isotopes in nuclear medicine is not known; therefore, as a proxy, we assume that it is proportional to the distribution of new cases of cancer in the relevant time period. This is because most investigations occur in the context of chronic disorders (including, very often, suspected

---

**Table 1** Summary of the Health Protection Agency’s review of the annual exposure of the UK population from all sources of ionising radiation

| Source                  | Average annual dose (µSv)* | Total (%) |
|-------------------------|---------------------------|-----------|
| Natural                 |                           |           |
| Cosmic                  | 330                       | 12        |
| Gamma                   | 350                       | 13        |
| Internal                | 250                       | 9.5       |
| Radon$^{a}$             | 1300                      | 50        |
| Artificial              |                           |           |
| Medical (diagnostic only)| 410                       | 15        |
| Occupational            | 6                         | 0.2       |
| Fallout                 | 6                         | 0.2       |
| Discharges              | 0.9                       | <0.1      |
| Consumer products       | 0.1                       | <0.1      |
| Total (rounded)         | 2700                      | 100       |

Based on Hughes et al (2005). $^{a}$Throughout this report the term ‘dose’ is used to indicate ‘committed effective dose’ unless otherwise specified. ‘Committed effective dose’ is derived by considering the absorbed dose (in joules per kilogram) and then multiplying it by a weighting factor to take account of the type of radiation involved. For sources that do not involve a uniform dose to the whole body, the doses to specific organs are further weighted according to factors recommended by the International Commission on Radiological Protection (ICRP, 2007). $^{b}$Assuming that living for a year in a home with a long-term average radon gas concentration of 20Bq m$^{-3}$ gives rise to a dose of about 1000 µSv.

**Table 2a** Lung cancer deaths in 2006 attributable to residential radon exposure in the UK

| Age (years) | Males | Females | Total |
|-------------|-------|---------|-------|
| <35         | ≈0.5  | ≈0.5    | 1     |
| 35–54       | 35    | 29      | 64    |
| 55–74       | 312   | 216     | 528   |
| ≥75         | 290   | 227     | 517   |
| All ages    | 637   | 473     | 1110  |

From Gray et al (2009).

**Table 2b** Estimated lung cancer cases in 2010 attributable to residential radon in the UK by age and sex

| Age (years) | Males | Females | Total number (%) |
|-------------|-------|---------|------------------|
| <35         | 0     | 1       | 1 (c<0.1)        |
| 35–54       | 20    | 21      | 41 (3)           |
| 55–74       | 436   | 342     | 778 (57)         |
| ≥75         | 302   | 254     | 556 (40)         |
| All ages    | 759   | 618     | 1376 (100)       |

Applying the PAFs calculated on the basis of radiation exposure in the mid-1990s to the cancers diagnosed in the UK in 2010 (Table 3) suggests that some 1861 cases, or 0.6% of all cancers, were caused by diagnostic radiation.
Table 3 Estimated cancer cases in the UK in 2010 by caused by diagnostic radiation

| Cancer                      | Radiation induced | Population | PAF (%) | No. of cases in 2010 | Excess attributable cases | Radiation induced | Population | PAF (%) | No. of cases in 2010 | Excess attributable cases |
|-----------------------------|-------------------|------------|---------|----------------------|---------------------------|-------------------|------------|---------|----------------------|---------------------------|
| Oesophagus                  | 0.002             | 0.67       | 0.3     | 5713                 | 17                        | 0.003             | 0.33       | 0.6     | 2819                 | 17                        |
| Stomach                     | 0.006             | 1.33       | 0.3     | 4467                 | 20                        | 0.005             | 0.55       | 0.9     | 2577                 | 23                        |
| Colon-rectum                | 0.014             | 1.56       | 0.5     | 22 127               | 199                       | 0.026             | 1.45       | 1.8     | 17 787               | 319                       |
| Liver                       | 0.001             | 0.18       | 0.6     | 2 270                | 13                        | 0.001             | 0.09       | 1.1     | 1 298                | 14                        |
| Lung                        | 0.007             | 5.50       | 0.1     | 22 273               | 28                        | 0.013             | 2.46       | 0.5     | 18 132               | 96                        |
| Female breast               | —                 | —          | —       | 2                       | —                         | 0.009             | 6.77       | 0.1     | 48 385               | 62                        |
| Bladder                     | 0.034             | 1.70       | 2.0     | 6713                 | 134                       | 0.009             | 0.56       | 1.7     | 2572                 | 43                        |
| Thyroid                     | <0.001            | 0.06       | 0.4     | 602                  | 2                         | 0.001             | 0.15       | 0.8     | 1776                 | 14                        |
| Leukaemia (excluding CLL)   | 0.008             | 0.60       | 1.3     | 3 002                | 40                        | 0.008             | 0.42       | 1.9     | 2 182                | 42                        |
| All above                   | 0.072             | 11.60      | 0.6     | 67 167               | 453                       | 0.074             | 12.77      | 0.6     | 97 528               | 630                       |
| Other radiation-inducible   | 0.051             | 8.80       | 0.6     | 79 828               | 462                       | 0.052             | 8.06       | 0.6     | 48 994               | 316                       |
| All cancers                 | —                 | —          | —       | 158 667              | 915                       | —                 | —          | —       | 155 584              | 946                       |

Table 4 Nuclear medicine procedures and estimated radiation doses

| Isotope                  | Average dose per procedure (mSv) | Annual collective dose 2003–4 (man Sv) |
|--------------------------|----------------------------------|---------------------------------------|
| Diagnostic               |                                  |                                       |
| Bone scan                | 99Tc ^m TcO4 Phosphates          | 3.0                                   | 601                                  |
| Myocardium               | 201TI Thallous chloride          | 12.9                                  | 209                                  |
| Myocardium               | 99Tc ^m TcO4 Tetrofosmin         | 3.1                                   | 196                                  |
| Myocardium               | 99Tc ^m TcO4 Sestamibi           | 3.7                                   | 92                                   |
| Lung perfusion           | 99Tc ^m TcO4 MAA                 | 0.9                                   | 85                                   |
| Tumours (PET)            | 18F FDG                         | 7.0                                   | 83                                   |
| Therapeutic              |                                  |                                       |
| Thyroid carcinoma        | 131I Iodide                     | 259.0 ^a                              | 437                                  |
| Thyrotoxicosis and goiter| 131I Iodide                     | 29.0 ^a                               | 305                                  |

Abbreviations: CLL = chronic lymphocytic leukaemia; PAF = population-attributable fraction. ^a Cumulative risks, based on exposures in 1991–6, from Berrington de González and Darby (2004). ^b Excluding non-melanoma skin cancer.

cancer). The populations in 5-year periods were taken to be equivalent to the census at the mid-year.

Figure 2 shows the estimated average individual effective dose to the whole body, in mSv, in 1982 and 2003–4 for males and females combined.

As we wish to estimate the effect of these estimated annual doses on cancer incidence in 2010, we estimated cumulative dose for specific age groups in 2005, thereby assuming a minimum 5-year latency between exposure and effect, as in BEIR VII (NRC, 2006). Cumulative exposures are small: <1 mSv before age 60, for example, and only about 6.5 mSv (males) and 4 mSv (females) by age 90. To estimate the effects of such radiation for cancers other than leukaemia, we used the cancer risk estimates, expressed as excess relative risks (ERRs) per Sv, from the report of UNSCEAR (2000) as summarised in Table 5.

The ERRs in 2005, together with the estimated doses, were applied to the observed numbers of solid cancer cases in 2010, to obtain the attributable cancers. The total was small – only about 4 excess cases in each sex.

For leukaemia, the relationship between risk and exposure is more complex, as ERR depends not only on dose but also on age at exposure, and time since exposure, and varies by sex. The BEIR VII report (NRC, 2006) used a model that expressed ERR as a linear-quadratic function of dose, with allowance for dependencies on sex, age at exposure and time since exposure. The preferred model took the form:

$$\text{ERR} = \beta D(1 + \delta D) \exp[\gamma t + \delta \log(t/25) + \phi \log(t/25)]$$

where $D$ is the dose (Sv), $t$ is the time since exposure (years), $e^\gamma = (e - 30)/10$ for $e < 30$, and $e^\phi = 0$ for $e \geq 30$, where $e$ is age at exposure in years; $\beta = 1.1$ for males, 1.2 for females; $\gamma = -0.40$ per decade (of age at exposure); $\delta = -0.48$; $\phi = 0.42$; and $\theta = 0.87$. 

© 2011 Cancer Research UK
British Journal of Cancer (2011) 105(52), S57 – S65
The model is valid only for the period ≥5 years following exposure. Therefore, the formula is used to calculate ERR in each age group, assuming annual doses estimated as described above, starting at those aged 5–9 years in 2010, who would have been first exposed at a mean age of 2.5. The BEIR VII committee (NRC, 2006) dealt with recent exposures by assuming that the excess absolute risk in the period 2–5 years following exposure is equal to that observed 5 years after exposure. Therefore, for the youngest age group (0–4 years), we derived the ERR by assuming that the excess absolute risk was the same as that for children aged 5–9 years who had been exposed at (mean) age 2.5. As exposures are assumed to have been occurring since 1950, we assume that the relative risks in each 5-year age group are multiplicative. That is, the relative risk in children aged 10–14 years in 2010 is the product of that in children exposed for 5 years at (mean) age 7.5 and that in children exposed for 10 years at (mean) age 2.5. As in the BEIR VII report (NRC, 2006), we assumed that the risk of CLL is not influenced by exposure to radiation, so the estimated ERRs were applied to the number of leukaemia cases in the UK, excluding CLL. The proportions of CLL cases among all leukaemia cases were taken from the published data for England for 2007 (ONS, 2010). We estimate that 7.7 cases of leukaemia in males (0.17% of all leukaemia) and 4.5 in females (0.14% of leukaemia cases) might be attributable to exposures received through nuclear medicine.

Adding the solid cancers and leukaemia cases, the total estimate for cancers attributable to radiation received through nuclear medicine exposures in 2010 is 11.5 in males (0.007% of all cancers) and 7.9 cancers in females (0.005% of all cancers).

For each of the 13 cancer sites, the numbers of second cancers were estimated by multiplying the numbers of cancer survivors in the UK at the beginning of 2007 (by cancer site, sex, age and time since diagnosis), the proportion that had received treatment by radiotherapy, and the relative risk of a second cancer associated with previous radiotherapy, based on the risk, relative to the general population (of the SEER registry areas), of developing a second cancer, for intervals <1, 1–4, 5–9 and 10+ years post diagnosis of the first cancer, for cancer survivors who had received radiotherapy (\(R_{rt}\)) and those who had not (\(R_{nt}\)). The excess risk of cancer due to radiotherapy, relative to the general population (ERR), is then given by

\[
\text{ERR} = \frac{R_{rt} - R_{nt}}{C_0}
\]

For each of the 13 cancer sites, the numbers of second cancers expected in the UK during 2010 associated with radiotherapy for a previous cancer were estimated using incidence rates for 2010 in the UK population and the relative risk of a second cancer in cancer survivors. To estimate the total number of second cancers, the numbers estimated to have occurred among survivors of the 13 selected cancer sites were multiplied by the ratio of the number of cancer survivors for England is described in Maddams et al (2009); age- and sex-specific population ratios between England and the UK were then used to scale these numbers to a UK level. The radiotherapy proportions from the Thames Cancer Registry were applied to the estimated numbers of cancer survivors in the UK at the beginning of 2007 to provide an estimate of the number of second cancers, with the total number now around 2 million and increasing by 3% per annum (Maddams et al, 2009). Many cancer survivors have received radiotherapy, and such treatment usually involves some incidental irradiation of the surrounding normal tissues, thus increasing the risk of a radiation-associated second cancer. Up until now, estimates of the radiation exposure of the UK population have not included exposure from radiotherapy, and the total number of cancers in the UK population associated with past radiation exposure from radiotherapy has not been assessed previously.

Maddams et al (2011) have prepared estimates of the cancer burden in the UK in 2007 due to radiotherapy. The method used was based on estimates of the numbers of cancer survivors in the UK at the beginning of 2007 (by cancer site, sex, age and time since diagnosis), the proportion that had received treatment by radiotherapy, and the relative risk of a second cancer associated with previous radiotherapy (from the United States Surveillance Epidemiology and End Results (SEER) programme (Curtis et al, 2006)). The methodology for preparing estimates of the number of cancer survivors for England is described in Maddams et al (2009); age- and sex-specific population ratios between England and the UK were then used to scale these numbers to a UK level. The radiotherapy proportions from the Thames Cancer Registry were applied to the estimated numbers of cancer survivors in the UK at the beginning of 2007 to provide an estimate of the number of second cancers, with the total number now around 2 million and increasing by 3% per annum (Maddams et al, 2009). Many cancer survivors have received radiotherapy, and such treatment usually involves some incidental irradiation of the surrounding normal tissues, thus increasing the risk of a radiation-associated second cancer. Up until now, estimates of the radiation exposure of the UK population have not included exposure from radiotherapy, and the total number of cancers in the UK population associated with past radiation exposure from radiotherapy has not been assessed previously.

Maddams et al (2011) have prepared estimates of the cancer burden in the UK in 2007 due to radiotherapy. The method used was based on estimates of the numbers of cancer survivors in the UK at the beginning of 2007 (by cancer site, sex, age and time since diagnosis), the proportion that had received treatment by radiotherapy, and the relative risk of a second cancer associated with previous radiotherapy (from the United States Surveillance Epidemiology and End Results (SEER) programme (Curtis et al, 2006)). The methodology for preparing estimates of the number of cancer survivors for England is described in Maddams et al (2009); age- and sex-specific population ratios between England and the UK were then used to scale these numbers to a UK level. The radiotherapy proportions from the Thames Cancer Registry were applied to the estimated numbers of cancer survivors in the UK at the beginning of 2007 to provide an estimate of the number of second cancers, with the total number now around 2 million and increasing by 3% per annum (Maddams et al, 2009). Many cancer survivors have received radiotherapy, and such treatment usually involves some incidental irradiation of the surrounding normal tissues, thus increasing the risk of a radiation-associated second cancer. Up until now, estimates of the radiation exposure of the UK population have not included exposure from radiotherapy, and the total number of cancers in the UK population associated with past radiation exposure from radiotherapy has not been assessed previously.

Maddams et al (2011) have prepared estimates of the cancer burden in the UK in 2007 due to radiotherapy. The method used was based on estimates of the numbers of cancer survivors in the UK at the beginning of 2007 (by cancer site, sex, age and time since diagnosis), the proportion that had received treatment by radiotherapy, and the relative risk of a second cancer associated with previous radiotherapy (from the United States Surveillance Epidemiology and End Results (SEER) programme (Curtis et al, 2006)). The methodology for preparing estimates of the number of cancer survivors for England is described in Maddams et al (2009); age- and sex-specific population ratios between England and the UK were then used to scale these numbers to a UK level. The radiotherapy proportions from the Thames Cancer Registry were applied to the estimated numbers of cancer survivors in the UK at the beginning of 2007 to provide an estimate of the number of second cancers, with the total number now around 2 million and increasing by 3% per annum (Maddams et al, 2009). Many cancer survivors have received radiotherapy, and such treatment usually involves some incidental irradiation of the surrounding normal tissues, thus increasing the risk of a radiation-associated second cancer. Up until now, estimates of the radiation exposure of the UK population have not included exposure from radiotherapy, and the total number of cancers in the UK population associated with past radiation exposure from radiotherapy has not been assessed previously.

Maddams et al (2011) have prepared estimates of the cancer burden in the UK in 2007 due to radiotherapy. The method used was based on estimates of the numbers of cancer survivors in the UK at the beginning of 2007 (by cancer site, sex, age and time since diagnosis), the proportion that had received treatment by radiotherapy, and the relative risk of a second cancer associated with previous radiotherapy (from the United States Surveillance Epidemiology and End Results (SEER) programme (Curtis et al, 2006)). The methodology for preparing estimates of the number of cancer survivors for England is described in Maddams et al (2009); age- and sex-specific population ratios between England and the UK were then used to scale these numbers to a UK level. The radiotherapy proportions from the Thames Cancer Registry were applied to the estimated numbers of cancer survivors in the UK at the beginning of 2007 to provide an estimate of the number of second cancers, with the total number now around 2 million and increasing by 3% per annum (Maddams et al, 2009). Many cancer survivors have received radiotherapy, and such treatment usually involves some incidental irradiation of the surrounding normal tissues, thus increasing the risk of a radiation-associated second cancer. Up until now, estimates of the radiation exposure of the UK population have not included exposure from radiotherapy, and the total number of cancers in the UK population associated with past radiation exposure from radiotherapy has not been assessed previously.
Table 6  Total numbers of second cancers expected in the UK in 2010, and those associated with the excess risk of cancer due to previous radiotherapy, by site of first cancer (13 selected cancer sites)

| First cancer type | Expected number of second cancers* | Number (%) associated with radiotherapy for first cancer |
|-------------------|-----------------------------------|--------------------------------------------------------|
| Males             |                                   |                                                        |
| Oral cavity and pharynx | 243                        | 47 (19.3)                                               |
| Oesophagus        | 85                                 | 8 (9.9)                                                |
| Stomach           | 177                                | 1 (0.6)                                                |
| Colorectal        | 1751                               | 44 (2.5)                                               |
| Larynx            | 391                                 | 32 (8.2)                                               |
| Lung              | 422                                 | 33 (7.7)                                               |
| Prostate          | 2006                               | 103 (5.1)                                              |
| Testes            | 217                                 | 23 (10.8)                                              |
| Hodgkin lymphoma  | 218                                 | 34 (16.0)                                              |
| Non-Hodgkin lymphoma | 391                           | 2 (0.5)                                                |
| Total (above 10 sites) | 5899                        | 328 (5.6)                                              |

| Females           |                                   |                                                        |
| Oral cavity and pharynx | 120                        | 20 (16.6)                                               |
| Oesophagus        | 45                                 | 6 (12.7)                                               |
| Stomach           | 74                                 | 0 (0.4)                                                |
| Colorectal        | 1248                               | 22 (1.7)                                               |
| Larynx            | 51                                 | 4 (1.7)                                                |
| Lung              | 150                                 | 8 (5.1)                                                |
| Breast            | 7429                               | 626 (8.4)                                              |
| Cervix uteri      | 526                                 | 90 (17.1)                                              |
| Corpus uteri      | 691                                 | 61 (8.9)                                               |
| Hodgkin lymphoma  | 145                                 | 28 (19.2)                                              |
| Non-Hodgkin lymphoma | 286                           | 1 (0.4)                                                |
| Total (above 11 sites) | 10766                       | 866 (8.0)                                              |

*Second cancers exclude those at the same site as the first, except for oral cavity and pharynx, colorectal and contralateral breast cancers. Also excluded are all leukaemias diagnosed within one year of any first cancer and all second cancers of other sites diagnosed within 5 years of any first cancer.

For these 13 sites, we estimate that there would have been 5899 cancers diagnosed in male survivors and 10 766 in female survivors and that, of these, 328 (5.6%) in men and 866 (8.0%) in women were associated with radiotherapy. These second cancers exclude those at the same site as the first, except for cancers of the oral cavity and pharynx, colorectal and contralateral breast.

The greatest number of second cancers in the UK in 2010 was among female survivors of breast cancer – 7429 cancers, of which 626 (8.4%) were associated with radiotherapy for the initial breast cancer; these represent 52.4% of the 1194 radiotherapy-associated cancers occurring among survivors of the 13 sites considered. There were also relatively large numbers of cancers occurring among survivors of colorectal cancer (2999: i.e., 1751 in males and 1248 in females) and prostate cancer (2006), although the percentages of these that were associated with radiotherapy were relatively small (2.2% and 5.1%, respectively). Of the second cancers that occurred among survivors of cancer of the oral cavity and pharynx, cervix uteri, and Hodgkin lymphoma, over 15% were estimated to be associated with radiotherapy for the first cancer.

Table 7 summarises the estimated numbers of cancers at different sites occurring in 2010 among the survivors of cancer at any of the 13 selected sites considered, and the numbers of these associated with radiotherapy. The most important among those estimated to be radiation-associated, in terms of numbers of cases, are cancers of the lung (274), oesophagus (159) and female breast (129). In all, 14.7% of second lung cancers were associated with radiotherapy, as were 31.1% of the oesophageal cancers. However, only 3.3% of breast cancers occurring in cancer survivors were radiotherapy-associated.

Table 8 (left-hand columns) shows the distribution of radiotherapy-related second cancers in 2010, in survivors of one of the 13 cancers considered, by age group and sex. The numbers are expressed as a percentage of all second cancers, and as a percentage of all cancers registered in the UK population. It also shows (right-hand columns) the estimated total number of radiotherapy-related second cancers occurring: 430 cases in men (0.26% of all new cancer cases) and 950 cases in women (0.60% of all new cancers).

Other forms of natural background radiation

As noted in Table 1, apart from radon, ionising radiation exposure comes naturally from cosmic rays, followed by terrestrial sources of gamma radiation, and 'internal' emissions.

Cosmic rays are particles that travel through interstellar space. The sun is a source of some of these particles; others come from exploding stars (supernovas). Exposure is increased by air travel at high altitudes.

The amount of terrestrial radiation from rocks and soils varies geographically depending on their local content of uranium. 'Internal' emissions come from radioactive isotopes in food and water and from the human body itself. Exposures from eating and drinking are due in part to the uranium and thorium series of radioisotopes present in food and drinking water. Carbon-14 is present in all living things, and accumulates in the food chain and...
contributes to the internal background dose from ionising radiation.

In estimating the effects of such radiation, we make the simplifying assumption that exposure is uniform throughout the body (rather than concentrated in specific organs), and use the cancer risk estimates, expressed as ERR per unit exposure, from the report of UNSCEAR (2006), as shown in Table 5.

Assuming an average annual dose of 0.93 mSv (Table 1), and a minimum 5-year latency between exposure and the increased risk of solid cancers, the excess incidence of solid cancers (i.e., excluding leukaemias) in the UK in 2010 is shown in Table 9. The total is 609 cases (or 0.2% of all cancers).

For leukaemia, we used the formula for ERR from BEIR described above in the section on Nuclear Medicine to calculate the relative risk in each age group, assuming an annual exposure of 0.93 mSv, starting at those aged 5–9 years in 2010, who would have been first exposed at a mean age of 2.5. For the youngest age group (0–4 years), we assumed that the excess absolute risk was the same as that for children aged 5–9 years who had been exposed at (mean) age 2.5 (see above). As exposure is continuous throughout life (rather than a single exposure to radiation at a given age), we assume that the risks in each 5-year age group are multiplicative (i.e., the risk in children aged 10–14 years in 2010 is the product of that in children exposed for 5 years at (mean) age 7.5 and of that in children exposed for 10 years at (mean) age 2.5). The estimated relative risks were applied to the number of leukaemia cases in the UK, excluding CLL.

We estimate that 316 cases of leukaemia in males (6.8% of all leukaemia) and 245 in females (7.7% of leukaemia cases) might be attributable to background radiation. Of these, 81 cases occurred in children aged <15 years (16.6% of leukaemia cases in this age group).

Adding the solid cancers and leukaemia cases, the total estimate is of 553 radiation-attributable cancers in males (0.35% of all cancers) and 617 cancers in females (0.40% of all cancers).

Summary of results

Table 10 shows the sum of the estimated numbers of cancers resulting from exposure to radon, to other forms of natural background radiation and from man-made sources: diagnostic radiology, radiotherapy and nuclear medicine.

In total, we estimate that approximately 5807 of the cancers diagnosed in the UK in 2010 were the result of such exposures, or around 1.8% of the total.

DISCUSSION

With respect to cancer causation, these calculations suggest that diagnostic radiology is the most important source of ionising radiation in the UK population. Our estimates are based on the work of Berrington de González and Darby (2004), whose estimates may be slightly high as they assumed that the life expectancy of individuals undergoing diagnostic radiology was the same as that of the general population. Any such overestimation is, however, small compared with the likely underestimation due to the application of risks based on exposures 15 years earlier to calculate the attributable fraction of cancers caused by diagnostic radiation occurring in 2010. For solid cancers, radiation-related excess risk starts to appear about 5 years after exposure in

### Table 8

| Age group (years) | Number | % of second cancers | % of all cancers\(^b\) | Number | % of all cancers\(^b\) |
|------------------|--------|---------------------|-----------------------|--------|-----------------------|
| **Males**        |        |                     |                       |        |                       |
| 0–34             | 0      | 4.7                 | 0.01                  | 1      | 0.02                  |
| 35–44            | 2      | 9.5                 | 0.05                  | 3      | 0.08                  |
| 45–54            | 9      | 10.9                | 0.08                  | 12     | 0.11                  |
| 55–64            | 36     | 9.0                 | 0.11                  | 45     | 0.14                  |
| 65–74            | 82     | 6.0                 | 0.16                  | 100    | 0.19                  |
| ≥75              | 199    | 4.9                 | 0.33                  | 269    | 0.44                  |
| **All ages**     | 328    | 5.6                 | 0.20                  | 430    | 0.26                  |
| **Females**      |        |                     |                       |        |                       |
| 0–34             | 0      | 7.1                 | 0.01                  | 1      | 0.02                  |
| 35–44            | 4      | 6.4                 | 0.05                  | 6      | 0.07                  |
| 45–54            | 29     | 6.6                 | 0.15                  | 34     | 0.18                  |
| 55–64            | 137    | 7.5                 | 0.44                  | 150    | 0.48                  |
| 65–74            | 255    | 8.7                 | 0.68                  | 277    | 0.74                  |
| ≥75              | 440    | 8.0                 | 0.79                  | 482    | 0.87                  |
| **All ages**     | 866    | 8.0                 | 0.55                  | 950    | 0.60                  |

\(^a\)Primary cancers as listed in Table 6. \(^b\)Excluding non-melanoma skin cancer.

### Table 9

| Cancer          | Excess attributable cases | PAF (%) | Excess attributable cases | PAF (%) |
|-----------------|---------------------------|---------|---------------------------|---------|
| Oesophagus       | 2.4                       | 0.04    | 0.7                       | 0.03    |
| Stomach          | 1.2                       | 0.03    | 0.3                       | 0.01    |
| Colorectum       | 19.6                      | 0.09    | 13.5                      | 0.08    |
| Liver            | 0.2                       | 0.01    | 0.1                       | 0.01    |
| Lung             | 27.7                      | 0.12    | 55.6                      | 0.31    |
| Bone             | <0.1                      | 0.01    | <0.1                      | 0.01    |
| Female breast    | —                         | —       | 235.5                     | 0.49    |
| Bladder          | 9.0                       | 0.13    | 1.2                       | 0.05    |
| Brain and CNS    | 0.6                       | 0.02    | 0.3                       | 0.01    |
| Thyroid          | <0.1                      | 0.01    | 0.3                       | 0.02    |
| All other solid\(^a\) | 176.6                     | 0.23    | 64.2                      | 0.14    |
| All solid\(^a\)  | 237.3                     | 0.15    | 371.9                     | 0.24    |

Abbreviations: CNS = central nervous system; PAF = population-attributable fraction. \(^a\)Excluding non-melanoma skin cancer.
therapeutically irradiated groups (Little, 1993; Weiss et al, 1994), while for leukaemia, the increase in risk following exposure certainly starts to appear within 5 years of exposure (Darby et al, 1987); therefore, a more appropriate period of exposure would be some 5 – 10 years earlier (i.e., 2000 – 5). The use of X-rays – particularly of computerised tomography (CT) scans, which result in higher organ doses of radiation than conventional single-film X-rays – has certainly increased between the period for which Berrington de González and Darby (2004) obtained detailed information on X-ray procedures (1991 – 6) and 2005. A recent report from the Health Protection Agency (Hart et al, 2010) estimated that the per caput dose from diagnostic radiology was about 400 mSv in 2008, compared with about 330 mSv in 1997–8. The increase is due mainly to the increasing use of CT examinations, which by 2008 accounted for 68% of the collective dose from all medical and dental X-ray examinations.

Radiation therapy is probably the second most important source of radiation-associated cancer (about one-quarter of the 5807 radiation-attributable cancers). Maddams et al (2011) provide a full discussion of the assumptions and limitations of the estimation, which include the following:

- The total number of survivors in the UK (i.e., the population at risk of a second cancer) is slightly underestimated, as the estimate used includes only those survivors diagnosed up to 35 years previously, although these account for 95% of all survivors.
- The UK prevalence of individuals with a past diagnosis of cancer who have, or have not, received radiotherapy was inferred from the proportions of cancer survivors who are recorded as having received radiotherapy in the database of the Thames Cancer Registry, and it was assumed that these proportions are reasonably representative of the national situation.
- The estimate of the relative risk of second cancers in survivors who had, and had not, received radiotherapy was derived from the experience of cancer patients in the US SEER population between 1973 and 2000. As radiation treatment was not randomised, selection bias could have resulted in differences between treatment groups with regard to other factors that affect second cancer risk – for example, smoking status, the clinical and pathological features of the initial cancer or concomitant disease.
- It was assumed that the nature of radiotherapy treatment for a given cancer was broadly similar in the US and the UK in the same time period (diagnosis of the initial cancer in 1973–2000).
- Estimation was based on data on prevalence and relative risk of radiotherapy for 13 specific cancer types, and the estimate for all cancer survivors involved a further assumption: that the rate of radiation-associated cancers among the sites not considered

| Table 10 Summary of estimated number of cancers in 2010 caused by exposure to ionising radiation, UK |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Type of cancer                  | Background      | Radon           | Diagnostic radiology | Radiotherapy | Nuclear medicine | All radiation |
|--------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| **Males**                       |                 |                 |                 |                 |                 |                 |
| Oesophagus                      | 2               | —               | 17              | 97              | 0.0             | 116             | 2.0            |
| Stomach                         | 1               | —               | 20              | 18              | 0.0             | 39              | 0.9            |
| Colon—rectum                   | 20              | —               | 199             | 33              | 0.3             | 252             | 1.1            |
| Liver                           | 0               | —               | 13              | —               | 0.0             | 13              | 0.6            |
| Lung                            | 28              | 759             | 28              | 113             | 0.5             | 928             | 4.2            |
| Breast (female)                 | —               | —               | —               | —               | —               | —               | —              |
| Bladder                         | 9               | —               | 134             | 30              | 1.3             | 174             | 2.6            |
| Thyroid                         | 0               | —               | 2               | —               | 0.0             | 2               | 0.4            |
| Leukaemia                       | 316             | —               | 40              | 0               | 7.7             | 364             | 7.8            |
| Other                           | 177             | —               | 462             | 140             | 1.6             | 780             | —              |
| All*                            | 553             | 759             | 915             | 430             | 11.5            | 2669            | 1.7            |
| **Females**                     |                 |                 |                 |                 |                 |                 |                 |
| Oesophagus                      | 1               | —               | 17              | 93              | 0.0             | 111             | 3.9            |
| Stomach                         | 0               | —               | 23              | 21              | 0.0             | 44              | 1.7            |
| Colon—rectum                   | 14              | —               | 319             | 53              | 0.0             | 385             | 2.2            |
| Liver                           | 0               | —               | 14              | —               | 0.0             | 15              | 1.1            |
| Lung                            | 56              | 618             | 96              | 206             | 0.8             | 976             | 5.4            |
| Breast (female)                 | 235             | —               | 62              | 141             | 1.9             | 440             | 0.9            |
| Bladder                         | 1               | —               | 43              | 16              | 0.1             | 60              | 2.3            |
| Thyroid                         | 0               | —               | 14              | —               | 0.0             | 15              | 0.8            |
| Leukaemia                       | 245             | —               | 42              | 43              | 4.5             | 334             | 10.4           |
| Other                           | 65              | —               | 316             | 376             | 0.5             | 757             | —              |
| All*                            | 617             | 618             | 945.5           | 950             | 7.9             | 3138            | 2.0            |
| **Persons**                     |                 |                 |                 |                 |                 |                 |                 |
| Oesophagus                      | 3               | —               | 34              | 190             | 0               | 227             | 2.7            |
| Stomach                         | 2               | —               | 44              | 39              | 0               | 84              | 1.2            |
| Colon—rectum                   | 33              | —               | 518             | 86              | 0               | 637             | 1.6            |
| Liver                           | 0               | —               | 0               | —               | —               | —               | —              |
| Lung                            | 83              | 1376            | 124             | 319             | 1               | 1905            | 4.7            |
| Breast (female)                 | 235             | —               | 62              | 141             | 2               | 440             | 0.9            |
| Bladder                         | 10              | —               | 177             | 46              | 1               | 235             | 2.5            |
| Thyroid                         | 0               | —               | 17              | 0               | 0               | 17              | 0.7            |
| Leukaemia                       | 561             | —               | 82              | 43              | 12              | 698             | 8.9            |
| Other                           | 242             | —               | 778             | 516             | 2               | 1537            | 0.0            |
| All*                            | 1170            | 1376            | 1861            | 1380            | 19              | 5807            | 1.8            |

Abbreviation: PAF = population-attributable fraction. *Excluding non-melanoma skin cancer.
et al (2009) have recently published an estimate of the fraction of childhood leukemia cases that might be attributable to natural background radiation. The precise result depended on the model used to estimate risk in the UK population, based on the results of the life span study of A-bomb survivors, but it is around 20% (in line with an earlier estimate (Wakeford, 2004)). The result of our rather more simplistic estimation approach (17%) is very similar, despite the assumption that the bone marrow dose of radiation from natural sources is constant throughout life. In fact, the radiation dose to the bone marrow of children – especially from ingested sources – is some 20–40% higher (depending on age) than in adults (Kendall et al, 2009), so that our estimates (and those of Wakeford et al, 2009) may be a little conservative. In any event, the small contribution of childhood leukemia to the total of radiation-related cancer means that such adjustments will have almost no effect on the totals in Table 10.

As we describe in the sections related to Methodology, the estimates of population exposure levels (dose) of radiation from the various sources considered rely on many extrapolations and assumptions. Furthermore, we take the conventional view that the relationship between cancer risk and dose at low levels of exposure follows that observed at higher levels, with no threshold effect, although there is very little direct evidence on this point. Despite these limitations, we believe that the overall estimate of around 5000 radiation-induced cancers in the UK (about 2% of the total) is of the correct order of magnitude.

See acknowledgements on page Si.

Conflict of interest

The authors declare no conflict of interest.
United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR) (2006) *Effects of Ionizing Radiation*. UNSCEAR 2006 Report to the General Assembly, with Scientific Annexes. United Nations: New York

Wakeford R (2004) The cancer epidemiology of radiation. *Oncogene* 23: 6404–6428

Wakeford R, Kendall GM, Little MP (2009) The proportion of childhood leukaemia incidence in Great Britain that may be caused by natural background ionizing radiation. *Leukemia* 23: 770–776

Weiss HA, Darby SC, Doll R (1994) Cancer mortality following x-ray treatment for ankylosing spondylitis. *Int J Cancer* 59: 327–338

Wrixon AD, Green BMR, Lomas PR, Miles JCH, Cliff KD, Francis EA, Driscoll CMH, James MC, O’Riordan MC (1988) *Natural Radiation Exposure in UK Dwellings. Report No. NRPB-R190*. National Radiological Protection Board: Chilton, England

This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/